AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
CGC   17.30 (-0.69%)
MU   49.46 (-2.45%)
TSLA   1,497.06 (-3.08%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
CGC   17.30 (-0.69%)
MU   49.46 (-2.45%)
TSLA   1,497.06 (-3.08%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
CGC   17.30 (-0.69%)
MU   49.46 (-2.45%)
TSLA   1,497.06 (-3.08%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
CGC   17.30 (-0.69%)
MU   49.46 (-2.45%)
TSLA   1,497.06 (-3.08%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
BA   175.65 (-1.56%)
Log in

NASDAQ:UROVUrovant Sciences Stock Price, Forecast & News

$9.20
-0.19 (-2.02 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.10
Now: $9.20
$9.70
50-Day Range
$8.67
MA: $10.38
$11.80
52-Week Range
$6.55
Now: $9.20
$15.98
Volume36,896 shs
Average Volume71,263 shs
Market Capitalization$283.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UROV
CUSIPN/A
CIKN/A
Phone44-20-7400-3347

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.90) per share

Profitability

Net Income$-146,740,000.00

Miscellaneous

Employees17
Market Cap$283.35 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive UROV News and Ratings via Email

Sign-up to receive the latest news and ratings for UROV and its competitors with MarketBeat's FREE daily newsletter.

Urovant Sciences (NASDAQ:UROV) Frequently Asked Questions

How has Urovant Sciences' stock been impacted by COVID-19 (Coronavirus)?

Urovant Sciences' stock was trading at $11.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UROV shares have decreased by 19.1% and is now trading at $9.20. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Urovant Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urovant Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Urovant Sciences.

When is Urovant Sciences' next earnings date?

Urovant Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Urovant Sciences.

How were Urovant Sciences' earnings last quarter?

Urovant Sciences Ltd (NASDAQ:UROV) announced its earnings results on Thursday, June, 18th. The company reported ($1.68) earnings per share for the quarter, missing analysts' consensus estimates of ($1.25) by $0.43. View Urovant Sciences' earnings history.

What price target have analysts set for UROV?

1 analysts have issued twelve-month price targets for Urovant Sciences' shares. Their forecasts range from $28.00 to $28.00. On average, they expect Urovant Sciences' stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 204.3% from the stock's current price. View analysts' price targets for Urovant Sciences.

Has Urovant Sciences been receiving favorable news coverage?

Headlines about UROV stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Urovant Sciences earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Urovant Sciences.

Are investors shorting Urovant Sciences?

Urovant Sciences saw a increase in short interest in June. As of June 30th, there was short interest totaling 881,800 shares, an increase of 6.5% from the June 15th total of 828,200 shares. Based on an average daily volume of 77,500 shares, the short-interest ratio is currently 11.4 days. Approximately 13.3% of the company's shares are short sold. View Urovant Sciences' Current Options Chain.

Who are some of Urovant Sciences' key competitors?

What other stocks do shareholders of Urovant Sciences own?

Who are Urovant Sciences' key executives?

Urovant Sciences' management team includes the following people:
  • Mr. Keith A. Katkin, CEO & Director (Age 48)
  • Ms. Christine G. Ocampo, Chief Accounting Officer and Principal Financial & Accounting Officer (Age 47)
  • Mr. Michael E. McFadden, Chief Commercial Officer of USI (Age 52)
  • Dr. David Hovland, Sr. VP of Global Regulatory Affairs
  • Ms. Nori Ebersole, Sr. VP & Chief HR Officer of USI (Age 56)

When did Urovant Sciences IPO?

(UROV) raised $150 million in an initial public offering on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO.

What is Urovant Sciences' stock symbol?

Urovant Sciences trades on the NASDAQ under the ticker symbol "UROV."

How do I buy shares of Urovant Sciences?

Shares of UROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Urovant Sciences' stock price today?

One share of UROV stock can currently be purchased for approximately $9.20.

How big of a company is Urovant Sciences?

Urovant Sciences has a market capitalization of $283.35 million. The company earns $-146,740,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Urovant Sciences employs 17 workers across the globe.

What is Urovant Sciences' official website?

The official website for Urovant Sciences is www.urovant.com.

How can I contact Urovant Sciences?

Urovant Sciences' mailing address is 11-12 ST. JAMES S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.